SUNNYVALE, Calif., January 26, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung tumors. Historically, the treatment of central lung tumors using gantry based Stereotactic Body Radiotherapy (SBRT) has been challenging and required a great deal of accuracy to avoid risks of damaging critical structures, such as the airway, esophagus and heart that can result in serious complications including death, leaving patients with fewer, less effective and sometimes only palliative options. This study, published in the January 2012 online issue of Radiotherapy & Oncology (commonly known as the Green Journal), demonstrated that the CyberKnife System, which leverages the Synchrony® Respiratory Tracking System and Lung Optimized Treatment to non-invasively track and correct for respiratory motion, allows clinicians to deliver lung SBRT to patients with central lung lesions with minimal toxicity, sparing surrounding healthy tissue, such as the esophagus, trachea and heart while also providing high levels of tumor control.
SUNNYVALE, Calif., January 18, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its second quarter of fiscal year 2012, ended December 31, 2011 on Wednesday, February 8, 2012 after the market closes.
SUNNYVALE, Calif., January 16, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that CHRISTUS MUGUERZA Hospital Alta Especialidad in Monterrey, Mexico has starting treating patients with the CyberKnife® Robotic Radiosurgery System. CHRISTUS MUGUERZA is the first center in Mexico now offering patients the benefits of the CyberKnife System to treat tumors anywhere in the body.
SUNNYVALE, Calif., January 10, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its CyberKnife® Robotic Radiosurgery System and TomoTherapy® System, solidifying the company’s footprint in the large and growing radiation oncology market. This, along with the company’s short- and long-term growth strategy, was presented yesterday by Accuray President and Chief Executive Officer Euan Thomson, Ph.D. as part of the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.
SUNNYVALE, Calif., January 9, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced publication of a study describing the clinical outcomes of prostate cancer patients treated with stereotactic body radiotherapy (SBRT) using Accuray’s CyberKnife® Robotic Radiosurgery System in a manner that uniquely mimics HDR (high dose rate) brachytherapy dosing within the prostate gland.
SUNNYVALE, Calif., January 5, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Needham Growth Conference in New York City on Thursday, January 12, 2012 at 8:40 a.m. EST/5:40 a.m. PST.
SUNNYVALE, Calif., December 22, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its president and chief executive officer, Euan S. Thomson, Ph.D., is scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 4:30 p.m. PST/7:30 p.m. EST.
SUNNYVALE, Calif., December 19, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that 23 leading medical centers globally have installed both a CyberKnife® Robotic Radiosurgery System and a TomoTherapy® System enabling the delivery of personalized treatment for the full spectrum of radiation oncology patients. These centers include smaller community sites in rural areas, mid-sized regional hospitals and large academic centers, indicating that centers of all sizes are benefiting from having both CyberKnife and TomoTherapy Systems.
SUNNYVALE, Calif., December 5, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Oppenheimer Healthcare Conference in New York City on Tuesday, December 13, 2011 at 1:00 p.m. EST/10:00 a.m. PST.
SUNNYVALE, Calif., November 30, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company received the Outstanding Innovative Improvement Award for its CyberKnife® Robotic Radiosurgery System at the 3rd Annual Employer Healthcare Congress, which took place October 25 – 28, 2011 in Chicago.
SUNNYVALE, Calif., November 22, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the 23rd Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 30, 2011 at 12:50 p.m. EST/9:50 a.m. PST.
SUNNYVALE, Calif., November 10, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its president and chief executive officer, Euan S. Thomson, Ph.D., is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 a.m. PST. Dr. Thomson is also scheduled to present at the Stephens Fall Investment Conference in New York City on Wednesday November 16, 2011 at 1:30 p.m. EST/10:30 a.m. PST.
SUNNYVALE, Calif., November 8, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the first quarter of fiscal 2012 that ended September 30, 2011. On June 10, 2011, Accuray completed the acquisition of TomoTherapy. As a result, the first quarter financial data presented reflect the consolidation of both Accuray and TomoTherapy. Non-GAAP results are provided to enhance understanding of Accuray’s ongoing core results of operations. For the first quarter of fiscal 2012, Accuray reported total consolidated GAAP revenue of $100.5 million and non-GAAP total revenue of $95.7 million. By comparison, for the quarter ended September 30, 2010 the sum of the revenue reported by Accuray and TomoTherapy as separate companies if combined totaled $81.7 million. Revenue in the first quarter of fiscal 2012 was driven by strong TomoTherapy System installations.
SUNNYVALE, Calif., October 26, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its TomoDirect treatment modality. More than 100 systems are now in use at leading cancer centers throughout the world, offering patients the option of treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy indications.
SUNNYVALE, Calif.—October 25, 2011—Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market the Dose Control System (DCS), a new feature for Accuray’s TomoTherapy® System that improves system performance.
SUNNYVALE, Calif., October 24 , 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its first quarter of fiscal year 2012, ended September 30, 2011 on Tuesday, November 8, 2011 after the market closes.
SUNNYVALE, Calif., October 19, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it ranked 274th on Deloitte’s Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010; during this period, Accuray grew 319 percent.
MIAMI and SUNNYVALE, Calif.— American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting—October 3, 2011—Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company is unveiling several enhancements to its CyberKnife® Robotic Radiosurgery System and TomoTherapy® Radiation Therapy System as well as rolling out its Diamond Plus Service Program to TomoTherapy customers* at The American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting. For the first time since the acquisition of TomoTherapy earlier this year, Accuray is showcasing both systems side-by-side in booth #225, demonstrating the full breadth and depth of the company’s advanced, personalized radiation treatment capabilities and services. ASTRO takes place October 2-6, 2011 at the Miami Beach Convention Center in Miami, Fla.
SUNNYVALE, Calif., September 26, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the JMP Securities Healthcare Conference in New York on Wednesday, September 28, 2011 at 9:30 a.m. EDT/6:30 a.m. PDT.
SUNNYVALE, Calif., September 23 , 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced details of the 2011 International Conference on TomoTherapy (ICT), which took place September 16-17, 2011 hosted by the University of Heidelberg, Germany’s oldest University and world famous research center for cancer and microbiology. University of Heidelberg was the first institution in Germany to adopt the TomoTherapy® System for daily image-guided, intensity-modulated radiation therapy (DIG-IMRT) with its installation in 2006. The university started treating patients on their second TomoTherapy System in January 2011.
SUNNYVALE, Calif., September 21 , 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that Kelly Londy has joined Accuray as Senior Vice President and Chief Commercial Officer, effective October 1, 2011.
SUNNYVALE, Calif., Sept. 19, 2011 - Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the fourth quarter and fiscal year ended June 30, 2011. It should be noted that the acquisition of TomoTherapy was completed on June 10, 2011. As a result, fourth quarter and fiscal 2011 financial data presented reflect the addition of TomoTherapy results from June 10, 2011 through June 30, 2011. Backlog, shipments and installations will be reflected for the full quarter for both Accuray and TomoTherapy.
SUNNYVALE, Calif., September 16, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 4:30 p.m. ET/1:30 p.m. PT.
SUNNYVALE, Calif., September 13, 2011 - Accuray Incorporated (Nasdaq: ARAY), today announced that it will report results for its fourth quarter and fiscal year 2011, ended June 30, 2011 on Monday, September 19, 2011 after the market closes.
SUNNYVALE, Calif., September 9, 2011 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, showcased new clinical research on its TomoTherapy® Radiation Therapy System at the 2011 Asia User Education Symposium, held September 2-4, 2011, in Singapore. The conference brought together close to 100 TomoTherapy System users from 34 hospitals across Asia for three days of education and insights on the growing body of evidence supporting the use of the TomoTherapy System for a wide range of clinical indications.